Five patients who experienced migrainelike attacks associated with electroconvulsive therapy (ECT) were treated using a novel nonpharmacologic therapy known as percutaneous electrical nerve stimulation (PENS). In this sham-controlled preliminary evaluation, PENS therapy proved to be a useful alternative to opioid analgesics for the acute treatment and/or prevention of ECT-induced headache. 
A link between depression and migraine has been recognized for more than a hundred years. (Table) . before the treatments was 6 to 7 on the VAS (Table) .
Immediately after each of the three PENS treatments, the VAS pain scores were zero, and 0, I, and 0 at 60 minutes after the ECT procedures (Table) . The pain-free period lasted for 10, 12, and 12 hours, respectively. Immediately after the three sham PENS treatments, the level of head pain was reported to be 5, 5, and 4, and 7, 8, and 7 at 60 minutes after the ECT procedures. Table. The levels of head pain before each treatment ranged between 8.0 and 9.5 on the 10 VAS. Immediately after the four PENS treatments, the VAS pain scores were 3. 2, 6, and 2, and 4, 2, 7, and 3 at 60 minutes after the ECT procedures (Table) . The duration of analgesia after the PENS treatments lasted from 3 to 6 hours. In contrast, immediately after the two sham PENS treatments, the VAS pain scores were 7 and 8, and increased to 9 and 9.5 at 60 minutes after the ECT procedures. Hz, or 100 Hz. The VAS head pain score before the treatment was 5 to 6 on the 10 scale. After the 30-minute PENS treatments, the VAS pain scores were 3, 2, and 3, and 0, 1, and 0.5 at 60 minutes after the ECT procedures (Table) .
The pain-free period lasted from 4 to 8 hours after each of the PENS treatments. After the sham PENS treatment, he refused to receive any further "acupuncture-type" treatments because he was dissatisfied with the pain relief. These five cases demonstrate that PENS therapy can be utilized to reduce the need for opioid analgesic medication to treat ECT-evoked headaches in patients "at risk" for developing this complication. Furthermore, PENS therapy may prove to be an effective alternative to serotonin agonist drugs in preventing migraine-type symptoms after ECT. In the future, prospective, randomized, controlled studies will be required to determine the relative efficacy of PENS and serotonin agonist therapies in the prophylactic management of ECT-evoked headaches.
